Therapeutic approaches in alzheimer’s disease: ? -amyloid peptide inhibitors

Abstract

In 2015, around 44 million people throughout the world, Dementia caused due to Alzheimer’s disease (AD) is associated with a progressive neurodegenerative disorder and this figure is estimated to double by the year 2050. Accumulation of β amyloid triggers the progression of AD through overproduction and aggregation which actively induce synaptic dysfunction leading to disease expression. The generation of Amyloid β-protein (Aβ), occurs through sequential cleavage of β- and γ-secretases while its removal is dependent on the proteolysis and lysosomal degradation system. The present review is focused on the treatments and strategies based on therapies being developed for treating AD which targets β- amyloid protein. These prospects include agents acting on (Aβ), blocking Tau oligomerization, acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor (NMDA) antagonist. Targeting Amyloid β-protein (Aβ) (Anti-Amyloid Approach), targeting amyloid aggregation, amyloid based vaccination therapy, Inhibition of Tau Phosphorylation, targeting amyloid clearance and cholesterol lowering drug.